XHKG
0954
Market cap20mUSD
Apr 09, Last price
0.32HKD
1D
8.47%
1Q
-20.99%
Jan 2017
-71.43%
Name
Changmao Biochemical Engineering Co Ltd
Chart & Performance
Profile
Changmao Biochemical Engineering Company Limited, together with its subsidiaries, produces and sells organic acids for food additive, chemical, and pharmaceutical industries in Mainland China, Europe, the Asia Pacific, the United States, and internationally. Its products include fumaric acid, maleic acid, L-malic acid, D-malic acid, DL-malic acid, L(+)-tartaric acid, D(-)-tartaric acid, DL-tartaric acid, L-aspartic acid, and aspartame that are used as food additives, pharmaceutical adjuvant, and active pharmaceutical ingredient, etc. The company is also involved in the research and development of medicine and nutraceutical products; production and sale of food additives; trading of organic acids; and property holding activities. Changmao Biochemical Engineering Company Limited was founded in 1992 and is headquartered in Changzhou, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 637,078 -12.73% | 730,034 33.22% | |||||||
Cost of revenue | 694,576 | 660,089 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (57,498) | 69,945 | |||||||
NOPBT Margin | 9.58% | ||||||||
Operating Taxes | 27,938 | 6,286 | |||||||
Tax Rate | 8.99% | ||||||||
NOPAT | (85,436) | 63,659 | |||||||
Net income | (86,057) -205.69% | 81,423 39.62% | |||||||
Dividends | (42,332) | ||||||||
Dividend yield | 13.78% | ||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 243,162 | 138,222 | |||||||
Long-term debt | 253,515 | 155,167 | |||||||
Deferred revenue | 13,584 | 40 | |||||||
Other long-term liabilities | |||||||||
Net debt | 400,121 | 229,760 | |||||||
Cash flow | |||||||||
Cash from operating activities | (2,349) | 19,633 | |||||||
CAPEX | (139,169) | (223,519) | |||||||
Cash from investing activities | (122,106) | (220,710) | |||||||
Cash from financing activities | 153,839 | 199,548 | |||||||
FCF | (240,261) | (197,431) | |||||||
Balance | |||||||||
Cash | 96,556 | 63,629 | |||||||
Long term investments | |||||||||
Excess cash | 64,702 | 27,127 | |||||||
Stockholders' equity | 460,288 | 589,101 | |||||||
Invested Capital | 1,095,116 | 1,039,995 | |||||||
ROIC | 9.71% | ||||||||
ROCE | 6.55% | ||||||||
EV | |||||||||
Common stock shares outstanding | 529,700 | 529,700 | |||||||
Price | 0.58 -17.14% | 0.70 2.94% | |||||||
Market cap | 307,226 -17.14% | 370,790 2.94% | |||||||
EV | 707,248 | 600,912 | |||||||
EBITDA | (14,753) | 102,147 | |||||||
EV/EBITDA | 5.88 | ||||||||
Interest | 7,583 | 2,669 | |||||||
Interest/NOPBT | 3.82% |